The company offers information and tools for individuals to learn about and explore their DNA.
Enabling individuals to discover ancestral origins and trace the lineage with a personalized analysis of DNA.
The company uses Illumina HumanOmniExpress-24 format chip that comprises a custom panel of probes for detecting genetic variations.
Its Personal Genome Service enables individuals to gain deeper insights into their ancestry and inherited traits.
The company has created the world’s largest crowdsourced platform for genetic research, with 80 percent of its customers electing to participate.
The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases.
The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas.
Find out what your DNA says about you and your family
See how your DNA breaks out across 2000+ regions worldwide
Discover DNA relatives from around the world
Share reports with family and friends
Learn how your DNA influences your facial features, taste, smell and other traits
Enterprise Value US$2.51B
PrimaryMarkets has sellers of this Unicorn Stock.
Minimum traction size – US$250,000.
All buyers must be Sophisticated/Accredited/Wholesale/Institutional Investors.
If interested please contact [email protected]
CEO & Co-Founder
Kathy Hibbs JD
Chief Legal & Regulatory Officer
Kenneth Hillan, M.B., Ch.B
Head of Therapeutics
Vice President & Chief Architect
Ask us a questionAsk Us a Question
Already a member?Login now
Become a memberRegister now